<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1803245060
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2024
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Opsutin
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        MACITENTAN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        5376.40
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Hetero Labs Limited Unit &#x2013; III" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Hetero Labs Limited Unit – III
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 2950]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Saudi Amarox
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Saudi Amarox
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        C02KX04
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Opsutin contains the active substance Macitentan, which belongs to the class of medicines called &ldquo;endothelin receptor antagonists&rdquo;.</p><p>&nbsp;</p><p>Opsutin is used for the long-term treatment of pulmonary arterial hypertension (PAH) in adults; it can be used on its own or with other medicines for PAH. PAH is high blood pressure in the blood vessels that carry blood from the heart to the lungs (the pulmonary arteries). In people with PAH, these arteries get narrower, so the heart has to work harder to pump blood through them. This causes people to feel tired, dizzy, and short of breath.</p><p>&nbsp;</p><p>Opsutin widens the pulmonary arteries, making it easier for the heart to pump blood through them. This lowers the blood pressure, relieves the symptoms and improves the course of the disease.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>1.&nbsp;&nbsp;&nbsp; Do not take Opsutin</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to Macitentan, Lecithin, soya or any of the other ingredients of this medicine (listed in&nbsp; section 6).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are pregnant, if you are planning to become pregnant, or if you could become pregnant because you are not using reliable birth control (contraception). See section &lsquo;Pregnancy and breastfeeding&rsquo;.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are breastfeeding. See section &lsquo;Pregnancy and breastfeeding&rsquo;.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have liver disease or if you have very high levels of liver enzymes in your blood. Talk to your doctor, who will decide whether this medicine is suitable for you.</p><p>If any of these apply to you, please tell your doctor.</p><p>&nbsp;</p><p>&nbsp;</p><p>Warnings and precautions</p><p>Talk to your doctor or pharmacist before taking Opsutin.</p><p>&nbsp;</p><p>&nbsp;</p><p><strong><u>You will need blood tests, as indicated by your doctor:</u></strong></p><p>Your doctor will take blood test before you start treatment with Opsutin and during treatment to test:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; whether you have anaemia (a reduced number of red blood cells)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; whether your liver is working properly</p><p>&nbsp;</p><p>If you have anaemia (a reduced number of red blood cells), you may have the following signs:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dizziness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fatigue/malaise/weakness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fast heart rate, palpitations</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pallor</p><p>If you notice any of these signs, <strong>tell your doctor.</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>Signs that your liver may not be working properly include:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling sick (nausea)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; vomiting</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fever</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pain in your stomach (abdomen)</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; yellowing of your skin or the whites of your eyes (jaundice)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dark-coloured urine</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; itching of your skin</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; unusual tiredness or exhaustion (lethargy or fatigue)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; flu-like syndrome (joint and muscle pain with fever)</p><p>If you notice any of these signs, <strong>tell your doctor immediately</strong>.</p><p>&nbsp;</p><p>&nbsp;</p><p>If you have kidney problems, talk to your doctor before using Opsutin. Macitentan may lead to more reduction of blood pressure and decrease in haemoglobin in patients with kidney problems.</p><p>&nbsp;</p><p>In patients with pulmonary veno-occlusive disease (obstruction of the lung veins), the use of medicines for treatment of PAH, including Opsutin, may lead to pulmonary oedema. If you have signs of pulmonary oedema when using Opsutin, such as a sudden, important increase in breathlessness and low oxygen, <strong>tell your doctor immediately</strong>. Your doctor may perform additional tests, and will determine what treatment regimen is most suitable for you.</p><p>&nbsp;</p><p>Children and adolescents</p><p>Do not give this medicine to children and adolescents below 18 years because Opsutin has not been tested in children.</p><p>&nbsp;</p><p>Elderly</p><p>There is limited experience with Opsutin in patients older than 75 years. Opsutin should be used with caution in this age group.</p><p>&nbsp;</p><p>Other medicines and Opsutin</p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicine. Opsutin can affect other medicines.</p><p>&nbsp;</p><p>If you take Opsutin together with other medicines including those listed below, the effects of Opsutin or the other medicines might be altered. Please talk to your doctor or pharmacist if you are taking any of the following medicines:</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rifampicin, clarithromycin, telithromycin, ciprofloxacin, erythromycin (antibiotics used to treat infections),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; phenytoin (a medicine used to treat seizures),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; carbamazepine (used to treat depression and epilepsy),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; St. John&rsquo;s Wort (an herbal preparation used to treat depression),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ritonavir, saquinavir (used to treat HIV infections),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nefazodone (used to treat depression),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ketoconazole (except shampoo), fluconazole, itraconazole, miconazole, voriconazole (medicines used against fungal infections)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; amiodarone (to control the heartbeat)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cyclosporine (used to prevent organ rejection after transplant)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; diltiazem, verapamil (to treat high blood pressure or specific heart problems)</p><p>&nbsp;</p><p>Opsutin with food</p><p>If you are taking piperine as a dietary supplement, this may alter how the body responds to some medicinal products, including Opsutin. Please talk to your doctor or pharmacist should this be the case.</p><p>&nbsp;</p><p>Pregnancy and breastfeeding</p><p>If you are pregnant or breastfeeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine.</p><p>&nbsp;</p><p>Opsutin may harm unborn babies conceived before, during or soon after treatment.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If it is possible you could become pregnant, use a reliable form of birth control (contraception) while you are taking Opsutin. Talk to your doctor about this.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not take Opsutin if you are pregnant or planning to become pregnant.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you become pregnant or think that you may be pregnant while you are taking Opsutin, or shortly after stopping Opsutin (up to 1 month), see your doctor immediately.</p><p>&nbsp;</p><p>If you are a woman who could become pregnant, your doctor will ask you to take a pregnancy test before you start taking Opsutin and regularly (once a month) while you are taking Opsutin.</p><p>&nbsp;</p><p>It is not known if Opsutin is transferred to breast milk. Do not breastfeed while you are taking Opsutin. Talk to your doctor about this.</p><p>&nbsp;</p><p>Driving and using machines</p><p>Opsutin can cause side effects such as headaches and hypotension (listed in section 4), and the symptoms of your condition can also make you less fit to drive.</p><p>&nbsp;</p><p>Opsutin contains lactose</p><p>Opsutin contains lactose monohydrate. If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine.</p><p>&nbsp;</p><p>Opsutin contains sodium</p><p>This medicine contains sodium that has to be taken into consideration by patients on a controlled sodium diet.</p><p>&nbsp;</p><p>Opsutin contain lecithin</p><p>This medicine contains lecithin derived from soya. If you are allergic to soya, do not use this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Opsutin should only be prescribed by a doctor experienced in the treatment of pulmonary arterial hypertension.</p><p>Always take this medicine exactly as your doctor has told you. Check with your doctor if you are not sure.</p><p>The recommended dose of Opsutin is one 10 mg tablet, once a day. Swallow the whole tablet, with a glass of water, do not chew or break the tablet. You can take Opsutin with or without food. It is best to take the tablet at the same time each day.</p><p>&nbsp;</p><p>If you take more Opsutin than you should</p><p>If you have taken more tablets than you have been told to take, you may experience headache, nausea, or vomiting. Ask your doctor for advice.</p><p>&nbsp;</p><p>If you forget to take Opsutin</p><p>&nbsp;</p><p>If you forget to take Opsutin, take a dose as soon as you remember, then continue to take your tablets at the usual times. Do not take a double dose to make up for a forgotten tablet.</p><p>&nbsp;</p><p>&nbsp;</p><p>If you stop taking Opsutin</p><p>Opsutin is a treatment that you will need to keep on taking to control your PAH. Do not stop taking Opsutin unless you have agreed this with your doctor.</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Uncommon side effects </strong>(may affect up to 1 in 100 people)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Allergic reactions (swelling around the eyes, face, lips, tongue or throat, itching and/or rash) If you notice any of these signs, tell your doctor immediately.</p><p>&nbsp;</p><p><strong>Very common side effects </strong>(may affect more than 1 in 10 people)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Anaemia (low number of red blood cells) or reduced haemoglobin</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Headache</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Bronchitis (inflammation of the airways)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Nasopharyngitis (inflammation of the throat and nasal passages)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Oedema (swelling), especially of the ankles and feet</p><p>&nbsp;</p><p><strong>Common side effects </strong>(may affect up to 1 in 10 people)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pharyngitis (inflammation of the throat)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Influenza (flu)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Urinary tract infection (bladder infection)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hypotension (low blood pressure)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Nasal congestion (blocked nose)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Elevated liver tests</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Leukopenia (decreased white blood cell counts)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Thrombocytopenia (decreased blood platelet counts)</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Reporting of side effects</p><p><strong>&nbsp;</strong></p><p>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly. By reporting side effects you can help provide more information on the safety of this medicine.</p><p>&nbsp;To report any side effect(s):</p><p>&bull;&nbsp; Saudi Arabia:</p><table border="1" cellspacing="0" cellpadding="0" align="left"><tbody><tr><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The National Pharmacovigilance and Drug Safety Centre (NPC)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SFDA Call Center: 19999</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: https://ade.sfda.gov.sa/</p></td></tr></tbody></table><p><strong><em>&nbsp;</em></strong></p><p><strong><em>&nbsp;</em></strong></p><p><strong><em>&nbsp;</em></strong></p><p><em>&nbsp;</em></p><p><em>&nbsp;</em></p><p>&bull;&nbsp; Other GCC States:</p><p><!--[if gte vml 1]><v:shapetype
 id="_x0000_t202" coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
 <v:stroke joinstyle="miter"/>
 <v:path gradientshapeok="t" o:connecttype="rect"/>
</v:shapetype><v:shape id="Text_x0020_Box_x0020_1" o:spid="_x0000_s1026"
 type="#_x0000_t202" style='position:absolute;left:0;text-align:left;
 margin-left:.55pt;margin-top:10.85pt;width:323.05pt;height:20pt;z-index:251658240;
 visibility:visible;mso-wrap-style:square;mso-width-percent:0;
 mso-height-percent:0;mso-wrap-distance-left:9pt;mso-wrap-distance-top:3.6pt;
 mso-wrap-distance-right:9pt;mso-wrap-distance-bottom:3.6pt;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:margin;
 mso-position-vertical:absolute;mso-position-vertical-relative:text;
 mso-width-percent:0;mso-height-percent:0;mso-width-relative:margin;
 mso-height-relative:margin;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
 <v:textbox>
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoListParagraph style='margin-top:0in;margin-right:0in;
    margin-bottom:0in;margin-left:.25in;margin-bottom:.0001pt;text-align:justify;
    text-indent:-.25in;line-height:150%;mso-list:l0 level1 lfo4'><![if !supportLists]><span
    lang=EN-IN style='mso-bidi-font-size:12.0pt;line-height:150%;mso-ansi-language:
    EN-IN'><span style='mso-list:Ignore'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </span></span></span><![endif]><span dir=LTR></span><span lang=EN-IN
    style='mso-bidi-font-size:12.0pt;line-height:150%;mso-ansi-language:EN-IN'>Please
    contact the relevant competent authority.<o:p></o:p></span></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
 <w:wrap type="square" anchorx="margin"/>
</v:shape><![endif]--><img width="435" height="31" alt="Text Box: -	Please contact the relevant competent authority." src="file:///C:/Users/Lenovo/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif" /></p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Store below 30&deg;C.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Keep out of reach of children.</p><p>&middot;&nbsp;&nbsp;&nbsp; Do not use this medicine after the expiry date which is stated on the pack after EXP. The expiry date refers to the last day of the month.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; This medicine does not require any special storage conditions.</p><p>&middot;&nbsp;&nbsp;&nbsp; Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>1.&nbsp;&nbsp; What Opsutin contains</p><p>The active substance is Macitentan</p><p>Each coated tablet contains 10 mg of Macitentan</p><p>&nbsp;</p><p><strong>The other ingredients are: </strong>Lactose Monohydrate, Sodium Starch Glycolate (Type-A), Povidone (K</p><p>&nbsp;</p><p>30), Polysorbate 80, Sodium Stearyl Fumarate, Purified Water.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Film-coating composition &ndash; </strong>Polyvinyl alcohol (E1203), Titanium Dioxide (E171), Talc (E553b), Lecithin (E322), Xanthan Gum (E415).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                What Opsutin looks like? Opsutin 10 mg:
White colored, round, biconvex, film coated tablets debossed with “HM” on one side and “21” on other side.
How supplied:
Opsutin is Supplied in 3 x 10’s Blister pack.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder Saudi Amarox Industrial Company </strong>Aljameah Street, Malaz quarter, Riyadh 12629, Saudi Arabia</p><p>Tel: +966 11 226 8850.</p><p>&nbsp;</p><p><strong>Manufacturer: </strong></p><p>&nbsp;&nbsp; Hetero Labs Limited Unit III, India</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in January 2023, Version 1
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL"><strong>ما هو أوبسوتين</strong></p><p dir="RTL">يحتوي أوبسوتين على المادة الفعالة ماسيتينتان ، والتي تنتمي إلى فئة الأدوية المسماة &quot;مضادات مستقبلات الإندوثلين&quot;.</p><p dir="RTL">يستخدم أوبسوتين في العلاج طويل الأمد لارتفاع ضغط الدم الشرياني الرئوي (PAH) عند البالغين ؛ يمكن استخدامه بمفرده أو مع أدوية أخرى لعلاج PAH. ارتفاع ضغط الدم الشرياني الرئوي PAH هو ارتفاع ضغط الدم في الأوعية الدموية التي تنقل الدم من القلب إلى الرئتين (الشرايين الرئوية). في الأشخاص الذين يعانون من PAH ، تضيق هذه الشرايين ، لذلك يتعين على القلب أن يعمل بجهد أكبر لضخ الدم من خلالها. هذا يجعل الناس يشعرون بالتعب والدوار وضيق التنفس.</p><p dir="RTL">يعمل أوبسوتين على توسعة الشرايين الرئوية ، مما يسهل على القلب ضخ الدم من خلالها. هذا يقلل من ضغط الدم ويخفف الأعراض ويحسن مسار المرض.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>&nbsp;</strong><strong>لا تستخدم أوبسوتين أقراص</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من حساسية تجاه ماسيتينتان أو ليسيثين أو فول الصويا أو أي من المكونات الأخرى لهذا الدواء (المدرجة في القسم 6).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت حاملاً ، أو إذا كنت تخططين للحمل ، أو إذا كنت تستطيعين الحمل لأنك لا تستخدمين وسيلة موثوقة لمنع الحمل (وسائل منع الحمل). انظر قسم &quot;الحمل والرضاعة الطبيعية&quot;.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مرضعة. انظر قسم &quot;الحمل والرضاعة الطبيعية&quot;.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابًا بمرض في الكبد أو إذا كان لديك مستويات عالية جدًا من إنزيمات الكبد في الدم. تحدث إلى طبيبك ، الذي سيقرر ما إذا كان هذا الدواء مناسبًا لك.</p><p dir="RTL">إذا كان أي من هذه ينطبق عليك ، فيرجى إخبار طبيبك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>التحذيرات والاحتياطات</strong></p><p dir="RTL">تحدث إلى طبيبك أو الصيدلي قبل تناول أوبسوتين.</p><p dir="RTL">ستحتاج إلى اجراء فحوصات دم ، كما أوضح طبيبك:</p><p dir="RTL">سيجري طبيبك فحص الدم قبل أن تبدأ العلاج باستخدام أوبسوتين وأثناء العلاج ليختبر:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ما إذا كنت تعاني من فقر الدم (انخفاض عدد خلايا الدم الحمراء).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ما إذا كان الكبد يعمل بشكل صحيح</p><p dir="RTL">إذا كنت تعاني من فقر الدم (انخفاض عدد خلايا الدم الحمراء) ، فقد تظهر عليك العلامات التالية:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دوار</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إرهاق / توعك / ضعف</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سرعة دقات القلب ، خفقان</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شحوب</p><p dir="RTL">إذا لاحظت أيًا من هذه العلامات ، أخبر طبيبك.</p><p dir="RTL">تشمل العلامات التي تدل على أن الكبد قد لا يعمل بشكل صحيح ما يلي:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالغثيان</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; القيء</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حُمى</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في معدتك (البطن).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اصفرار بشرتك أو بياض عينيك (اليرقان).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; البول داكن اللون</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حكة في جلدك</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التعب أو الإرهاق غير العادي (الخمول أو التعب).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; متلازمة شبيهة بالإنفلونزا (آلام المفاصل والعضلات مع الحمى).</p><p dir="RTL">إذا لاحظت أيًا من هذه العلامات ، أخبر طبيبك على الفور.</p><p dir="RTL">إذا كنت تعاني من مشاكل في الكلى ، تحدث إلى طبيبك قبل استخدام أوبسوتين. ماسيتينتان قد يؤدي إلى مزيد من الانخفاض في ضغط الدم وانخفاض الهيموجلوبين في المرضى الذين يعانون من مشاكل في الكلى.</p><p dir="RTL">في المرضى الذين يعانون من مرض انسداد الوريد الرئوي (انسداد الأوردة الرئوية) ، قد يؤدي استخدام الأدوية لعلاج ارتفاع ضغط الدم الشرياني الرئوي PAH ، بما في ذلك أوبسوتين ، إلى وذمة رئوية. إذا ظهرت عليك علامات الوذمة الرئوية أثناء استخدام أوبسوتين ، مثل زيادة مفاجئة وحادة في ضيق التنفس وانخفاض الأكسجين ، أخبر طبيبك على الفور. قد يقوم طبيبك بإجراء اختبارات إضافية ، وسيحدد نظام العلاج الأنسب لك.</p><p dir="RTL"><strong>الأطفال والمراهقون</strong></p><p dir="RTL">يجب عدم استخدام هذا الدواء للأطفال والمراهقين الذين تقل أعمارهم عن 18 عامًا لأنه لم يتم اختبار أوبسوتين على الأطفال.</p><p dir="RTL"><strong>كبار السن</strong></p><p dir="RTL">هناك خبرة محدودة عن استخدام أوبسوتين في المرضى الذين تزيد أعمارهم عن 75 عامًا. يجب استخدام أوبسوتين بحذر في هذه الفئة العمرية.</p><p dir="RTL"><strong>الأدوية الأخرى وتناول أوبسوتين أقراص</strong></p><p dir="RTL">أخبر طبيبك أو الصيدلي إذا كنت تتناول أو تناولت مؤخرًا أو قد تتناول أي دواء آخر.</p><p dir="RTL">يمكن أن يؤثر أوبسوتين على الأدوية الأخرى.</p><p dir="RTL">إذا كنت تتناول أوبسوتين مع أدوية أخرى بما في ذلك تلك المذكورة أدناه ، فقد يتم تغيير تأثير أوبسوتين أو الأدوية الأخرى. يرجى التحدث مع طبيبك أو الصيدلي إذا كنت تتناول أي من الأدوية التالية:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ريفامبيسين ، كلاريثروميسين ، تيليثروميسين ، سيبروفلوكساسين ، إريثروميسين (مضادات حيوية تستخدم لعلاج الالتهابات).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الفينيتوين (دواء يستخدم لعلاج النوبات).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كاربامازيبين (يستخدم لعلاج الاكتئاب والصرع).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نبتة العرن المثقوب (مستحضر عشبي يستخدم لعلاج الاكتئاب).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ريتونافير ، ساكوينافير (المستخدمة لعلاج عدوى فيروس نقص المناعة البشرية).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نيفازودون (يستعمل لعلاج الإكتئاب).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الكيتوكونازول (باستثناء الشامبو) ، فلوكونازول ، إيتراكونازول ، ميكونازول ، فوريكونازول (الأدوية المستخدمة ضد الالتهابات الفطرية).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأميودارون (للتحكم في ضربات القلب).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; السيكلوسبورين (يستخدم لمنع رفض العضو بعد الزرع).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ديلتيازيم ، فيراباميل (لعلاج ارتفاع ضغط الدم أو مشاكل قلبية معينة).</p><p dir="RTL"><strong>تناول أوبسوتين مع الطعام</strong></p><p dir="RTL">إذا كنت تتناول بيبيرين كمكمل غذائي ، فقد يغير ذلك من كيفية استجابة الجسم لبعض المنتجات الطبية ، بما في ذلك أوبسوتين. يرجى التحدث مع طبيبك أو الصيدلي إذا كان هذا هو الحال.</p><p dir="RTL"><strong>الحمل والرضاعة</strong></p><p dir="RTL">إذا كنت حاملاً أو مرضعة ، تعتقدين أنك حامل أو تخططين لإنجاب طفل ، اسألي طبيبك للحصول على المشورة قبل تناول هذا الدواء.</p><p dir="RTL">قد يؤذي أوبسوتين الأطفال الذين لم يولدوا بعد وذلك قبل أو أثناء أو بعد فترة وجيزة من العلاج.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان من الممكن أن تصبحي حاملاً ، فاستخدمي وسيلة موثوقة لتحديد النسل (وسائل منع الحمل) أثناء تناول أوبسوتين. تحدث إلى طبيبك عن هذا.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تتناولي أوبسوتين إذا كنت حاملاً أو تخططين للحمل.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا أصبحت حاملاً أو تعتقدين أنك قد تكونين حاملاً أثناء تناول أوبسوتين ، أو بعد فترة وجيزة من التوقف عن أوبسوتين (حتى شهر واحد) ، راجعي طبيبك على الفور.</p><p dir="RTL">إذا كنت امرأة يمكن أن تصبحين حاملاً ، سيطلب منك طبيبك إجراء اختبار الحمل قبل البدء في تناول أوبسوتين وبانتظام (مرة واحدة في الشهر) أثناء تناولك أوبسوتين.</p><p dir="RTL">من غير المعروف ما إذا كان أوبسوتين ينتقل إلى حليب الأم. يجب عدم القيام بالرضاعة الطبيعية أثناء تناول أوبسوتين. تحدث إلى طبيبك عن هذا.</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">يمكن أن يسبب أوبسوتين آثارًا جانبية مثل الصداع وانخفاض ضغط الدم (مدرج في القسم 4) ، كما أن أعراض حالتك يمكن أن تجعلك أقل لياقة للقيادة.</p><p dir="RTL"><strong>محتوي أوبسوتين من </strong><strong>اللاكتوز</strong></p><p dir="RTL">يحتوي أوبسوتين على اللاكتوز مونوهيدرات. إذا أخبرك طبيبك أن لديك حساسية تجاه بعض السكريات ، فاتصل بطبيبك قبل تناول هذا الدواء.</p><p dir="RTL"><strong>محتوي أوبسوتين من الصوديوم</strong></p><p dir="RTL">يحتوي هذا الدواء على الصوديوم الذي يجب أن يؤخذ في الاعتبار من قبل المرضى الذين يتبعون أنظمة غذائية الخاضعة للرقابة بالنسبة للصوديم.</p><p dir="RTL"><strong>محتوي أوبسوتين من </strong><strong>الليسيثين</strong></p><p dir="RTL">يحتوي أوبسوتين على الليسيثين المشتق من فول الصويا. إذا كان لديك حساسية من فول الصويا ، لا تستخدم هذا الدواء.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يجب أن يتم وصف أوبسوتين فقط من قبل طبيب متمرس في علاج ارتفاع ضغط الدم الشرياني الرئوي.</p><p dir="RTL">احرص دائمًا على تناول هذا الدواء تمامًا كما أخبرك طبيبك. استشر طبيبك إذا لم تكن متأكدًا.</p><p dir="RTL">الجرعة الموصى بها من أوبسوتين هي 10 ملجرام القرص مرة في اليوم. ابتلع القرص كله ، مع كوب من الماء ، لا تمضغ القرص الصلب أو تكسره. يمكنك تناول أوبسوتين مع الطعام أو بدونه. من الأفضل تناول القرص في نفس الوقت كل يوم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تناول جرعة زائدة من أوبسوتين أقراص</strong></p><p dir="RTL">إذا كنت قد تناولت أقراصًا أكثر مما ينبغي ، فقد تواجه صداعًا أو غثيانًا أو قيئًا. اسأل طبيبك للحصول على المشورة.</p><p dir="RTL"><strong>إذا نسيت أن تتناول أوبسوتين</strong></p><p dir="RTL">إذا نسيت تناول أوبسوتين ، فتناول جرعة بمجرد أن تتذكرها ، ثم استمر في تناول أقراصك في الأوقات المعتادة. لا تتناول جرعة مضاعفة لتعويض القرص المنسي.</p><p dir="RTL"><strong>التوقف عن تناول أوبسوتين</strong></p><p dir="RTL">أوبسوتين هو العلاج الذي ستحتاج إلى الاستمرار في تناوله للتحكم في حالة PAH الخاص بك. لا تتوقف عن تناول أوبسوتين إلا إذا أخبرك طبيبك بذلك.</p><p dir="RTL">إذا كان لديك أي أسئلة أخرى حول استخدام هذا الدواء ، اسأل طبيبك أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية ، يمكن أن يسبب هذا الدواء آثارًا جانبية ، على الرغم من عدم حدوثها لدى الجميع.</p><p dir="RTL">أعراض جانبية غير شائعة (قد تظهر لدى حتى 1 من كل 100 شخص).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات تحسسية (انتفاخ حول العينين والوجه والشفتين واللسان أو الحلق والحكة و / أو الطفح الجلدي).</p><p dir="RTL">إذا لاحظت أيًا من هذه العلامات ، أخبر طبيبك على الفور.</p><p dir="RTL">أعراض جانبية شائعة جدًا (قد تظهر لدى أكثر من 1 من كل 10 أشخاص).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقر الدم (انخفاض عدد خلايا الدم الحمراء) أو انخفاض الهيموجلوبين</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صداع الراس</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الشعب الهوائية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب البلعوم الأنفي (التهاب الحلق والممرات الأنفية).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وذمة (انتفاخ) وخاصة في الكاحلين والقدمين</p><p dir="RTL">أعراض جانبية شائعة (قد تظهر لدى حتى 1 من كل 10 أشخاص).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب البلعوم (التهاب الحلق).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الانفلونزا</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب المسالك البولية (التهاب المثانة).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض ضغط الدم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احتقان الأنف (انسداد الأنف).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نتائج اختبارات الكبد المرتفعة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قلة الكريات البيض (انخفاض عدد خلايا الدم البيضاء).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قلة الصفيحات (انخفاض عدد الصفائح الدموية)</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p><strong>الإبلاغ عن الآثار الجانبية: </strong></p><p>إذا زادت حدة أي من هذه الأعراض الجانبية ، أو لاحظت ظهور أعراض جانبية غير ما تم ذكره في هذه النشرة ، يرجى إبلاغ الطبيب المعالج أو الصيدلي. وهذا يشمل أي آثار جانبية محتملة غير مدرجة في هذه النشرة. يمكنك أيضا الإبلاغ عن الآثار الجانبية مباشرة. بالإبلاغ عن الآثار الجانبية يمكنك المساعدة في توفير مزيد من المعلومات حول أمان هذا الدواء.</p><p dir="RTL"><strong>للإبلاغ حول الأعراض الجانبية التي قد تحدث يرجى التواصل عبر العناوين التالية</strong><strong>:</strong></p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>المملكة العربية السعودية</strong><strong>:</strong></p><p dir="RTL">&nbsp;</p><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p dir="RTL">المركز الوطني للتيقظ الدوائي :</p><p dir="RTL">مركز الاتصال الموحد: 19999</p><p dir="RTL">البريد الإلكتروني: npc.drug@sfda.gov.sa</p><p dir="RTL">الموقع الإلكتروني: https://ade.sfda.gov.sa</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p>&nbsp;</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p>&nbsp;<p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>دول الخليج العربي الأخرى</strong><strong>:</strong></p></p><p dir="RTL">&nbsp;</p><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>الرجاء الاتصال بالجهات الوطنية في كل دولة</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p>&nbsp;</p><p dir="RTL"><strong>&nbsp;</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يحفظ في درجة حرارة أقل من 30 درجة مئوية.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احفظ هذا الدواء بعيدًا عن رؤية ومتناول أيدي الأطفال.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المذكور على العبوة بعد EXP. يشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من الشهر.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تتخلص من الأدوية في مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد بحاجة إليها. ستساعد هذه الإجراءات في حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>ماذا يحتوي أوبسوتين أقراص على:</strong></p><p dir="RTL">المادة الفعالة هي ماسيتينتان.</p><p dir="RTL"><strong>أوبسوتين أقراص</strong><strong> 10 ملجرام</strong></p><p dir="RTL">يحتوي كل قرص مغطى بطبقة رقيقة على 10 ملجرام ماسيتينتان.</p><p dir="RTL">الصواغات الأخرى: لاكتوز مونوهيدرات ، نشا الصوديوم جليكولات (النوع أ) ، بوفيدون (K-30) ، بولي سوربات 80 ، الصوديوم ستيريل فومارات ، والمياه النقية.</p><p dir="RTL">الصواغات الأخرى لطبقة الكسوة الخارجية هي:- كحول بولي فينيل (E1203) ، ثاني أكسيد التيتانيوم (E171) ، تلك (E553b) ، ليسيثين (E322) ، صمغ الزانثان.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>ما هو شكل أوبسوتين أقراص؟</strong></p><p dir="RTL"><strong>أوبسوتين أقراص</strong><strong> 10 ملجرام</strong></p><p dir="RTL">أقراص مستديرة مطلية باللون الأبيض ، محدبة الوجهين ، مغلفة بطبقة رقيقة منقوش عليها &quot;HM&quot; على جانب واحد و &quot;21&quot; على الجانب الآخر.</p><p dir="RTL"><strong>كيفية توفير أوبسوتين أقراص؟</strong>:</p><p dir="RTL">يتم توفير أوبسوتين في شرائط داخل علب تحتوي على 10 x 3 أقراص.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;</p><p><strong>صاحب حق التسويق:</strong></p><p dir="RTL"><strong>شركة اماروكس السعودية الصناعية</strong></p><p>شارع الجامعة ، الملز&nbsp;</p><p>الرياض 12629 ، المملكة العربية السعودية.</p><p dir="RTL">تليفون: +966 11 226 8850</p><p dir="RTL"><strong>الشركة المصنعة: </strong></p><p dir="RTL">شركة هيتيرولاب الوحدة الثالثة، الهند</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت مراجعة هذه النشرة في يناير 2023 ، نسخة 1
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Opsutin (Macitentan tablets 10 mg)
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each coated tablet contains 10 mg of Macitentan For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                White colored, round, biconvex, film coated tablets debossed with “HM” on one side and “21” on other side..
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Opsumit, as monotherapy or in combination, is indicated for the long-term treatment of pulmonary arterial hypertension (PAH) in adult patients of WHO Functional Class (FC) II to III. Efficacy has been shown in a PAH population including idiopathic and heritable PAH, PAH associated with connective tissue disorders, and PAH associated with corrected simple congenital heart disease (see section 5.1).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Treatment should only be initiated and monitored by a physician experienced in the treatment of PAH.</p><p><u>Posology</u></p><p>The recommended dose is 10 mg once daily. <u>Special populations</u></p><p><em>Elderly</em></p><p>No dose adjustment is required in patients over the age of 65 years (see section 5.2). There is limited clinical experience in patients over the age of 75 years. Therefore, Opsumit should be used with caution in this population (see section 4.4).</p><p>&nbsp;</p><p>&nbsp;</p><p><em>Hepatic impairment</em></p><p>Based on pharmacokinetic (PK) data, no dose adjustment is required in patients with mild, moderate or severe hepatic impairment (see sections 4.4 and 5.2). However, there is no clinical experience with the use of macitentan in PAH patients with moderate or severe hepatic impairment. Opsumit must not be initiated in patients with severe hepatic impairment, or clinically significant elevated hepatic aminotransferases (greater than 3 times the Upper Limit of Normal (&gt; 3 &times; ULN); see sections 4.3 and 4.4).</p><p>&nbsp;</p><p><em>Renal impairment</em></p><p>Based on PK data, no dose adjustment is required in patients with renal impairment. There is no clinical experience with the use of macitentan in PAH patients with severe renal impairment. The use of Opsumit is not recommended in patients undergoing dialysis (see sections 4.4 and 5.2).</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p>The safety and efficacy of macitentan in children and adolescents below 18 years have not yet been established. No data are available.</p><p>&nbsp;</p><p><u>Method of administration</u></p><p>The film-coated tablets are not breakable and are to be swallowed whole, with water. They may be taken with or without food.</p><p>&nbsp;</p><p>Opsumit should be taken every day at about the same time. If the patient misses a dose of Opsumit, the patient should be told to take it as soon as possible and then take the next dose at the regularly scheduled time. The patient should be told not to take two doses at the same time if a dose has been missed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                ●	Hypersensitivity to the active substance, soya or to any of the excipients listed	in section 6.1.
 

●	Pregnancy (see section 4.6).
●	Women of childbearing potential who are not using reliable contraception (see sections 4.4 and 4.6).
●	Breastfeeding (see section 4.6).
●	Patients with severe hepatic impairment (with or without cirrhosis) (see section 4.2).
●	Baseline values of hepatic aminotransferases (aspartate aminotransferases (AST) and/or alanine aminotransferases (ALT) > 3 × ULN) (see sections 4.2 and 4.4).

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The benefit/risk balance of macitentan has not been established in patients with WHO class I functional status of pulmonary arterial hypertension.</p><p>&nbsp;</p><p><u>Liver function</u></p><p>Elevations of liver aminotransferases (AST, ALT) have been associated with PAH and with endothelin receptor antagonists (ERAs). Opsumit is not to be initiated in patients with severe hepatic impairment or elevated aminotransferases (&gt; 3 &times; ULN) (see sections 4.2 and 4.3) and is not recommended in patients with moderate hepatic impairment. Liver enzyme tests should be obtained prior to initiation of Opsumit.</p><p>&nbsp;</p><p>Patients should be monitored for signs of hepatic injury and monthly monitoring of ALT and AST is recommended. If sustained, unexplained, clinically relevant aminotransferase elevations occur, or if elevations are accompanied by an increase in bilirubin &gt; 2 &times; ULN, or by clinical symptoms of liver injury (e.g., jaundice), Opsumit treatment should be discontinued.</p><p>&nbsp;</p><p>Reinitiation of Opsumit may be considered following the return of hepatic enzyme levels to within the normal range in patients who have not experienced clinical symptoms of liver injury. The advice of a hepatologist is recommended.</p><p>&nbsp;</p><p><u>Haemoglobin concentration</u></p><p>&nbsp;</p><p>&nbsp;</p><p>Decrease in haemoglobin concentrations has been associated with endothelin receptor antagonists (ERAs) including macitentan (see section 4.8). In placebo-controlled studies, macitentan-related decreases in haemoglobin concentration were not progressive, stabilised after the first 4&ndash;12 weeks of treatment and remained stable during chronic treatment. Cases of anaemia requiring blood cell transfusion have been reported with macitentan and other ERAs. Initiation of Opsumit is not recommended in patients with severe anaemia. It is recommended that haemoglobin concentrations be measured prior to initiation of treatment and tests repeated during treatment as clinically indicated.</p><p>&nbsp;</p><p><u>Pulmonary veno-occlusive disease</u></p><p>Cases of pulmonary oedema have been reported with vasodilators (mainly prostacyclins) when used in patients with pulmonary veno-occlusive disease. Consequently, if signs of pulmonary oedema occur when macitentan is administered in patients with PAH, the possibility of pulmonary veno-occlusive disease should be considered.</p><p>&nbsp;</p><p><u>Use in women of childbearing potential</u></p><p>Opsumit treatment should only be initiated in women of childbearing potential when the absence of pregnancy has been verified, appropriate advice on contraception provided, and reliable contraception is practised (see sections 4.3 and 4.6). Women should not become pregnant for 1 month after discontinuation of Opsumit. Monthly pregnancy tests during treatment with Opsumit are recommended to allow the early detection of pregnancy.</p><p>&nbsp;</p><p><u>Concomitant use with strong CYP3A4 inducers</u></p><p>In the presence of strong CYP3A4 inducers reduced efficacy of macitentan could occur. The combination of macitentan with strong CYP3A4 inducers (e.g., rifampicin, St. John&rsquo;s wort, carbamazepine, and phenytoin) should be avoided (see section 4.5).</p><p>&nbsp;</p><p><u>Concomitant use with strong CYP3A4 inhibitors</u></p><p>&nbsp;</p><p>&nbsp;</p><p>Caution should be exercised when macitentan is administered concomitantly with strong CYP3A4 inhibitors (e.g., itraconazole, ketoconazole, voriconazole, clarithromycin, telithromycin, nefazodone, ritonavir, and saquinavir) (see section 4.5).</p><p>&nbsp;</p><p><u>Concomitant use with moderate dual or combined CYP3A4 and CYP2C9 inhibitors</u></p><p>Caution should be exercised when macitentan is administered concomitantly with moderate dual inhibitors of CYP3A4 and CYP2C9 (e.g., fluconazole and amiodarone) (see section 4.5).</p><p>&nbsp;</p><p>Caution should also be exercised when macitentan is administered concomitantly with both a moderate CYP3A4 inhibitor (e.g., ciprofloxacin, cyclosporine, diltiazem, erythromycin, verapamil) and moderate CYP2C9 inhibitor (e.g., miconazole, piperine) (see section 4.5).</p><p>&nbsp;</p><p><u>Renal impairment</u></p><p>Patients with renal impairment may run a higher risk of experiencing hypotension and anaemia during treatment with macitentan. Therefore, monitoring of blood pressure and haemoglobin should be considered. There is no clinical experience with the use of macitentan in PAH patients with severe renal impairment. Caution is recommended in this population. There is no experience with the use of macitentan in patients undergoing dialysis, therefore Opsumit is not recommended in this population (see sections 4.2 and 5.2).</p><p>&nbsp;</p><p><u>Elderly</u></p><p>There is limited clinical experience with macitentan in patients over the age of 75 years, therefore Opsumit should be used with caution in this population (see section 4.2).</p><p>&nbsp;</p><p><u>Excipients</u></p><p>Opsumit contains lactose. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicinal product.</p><p>&nbsp;</p><p>&nbsp;</p><p>Opsumit contains soya bean lecithin. If a patient is hypersensitive to soya, Opsumit must not be used (see section 4.3).</p><p>&nbsp;</p><p>This medicinal product contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially&lsquo;sodium-free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em><u>In vitro </u></em><u>studies</u></p><p>The cytochrome P450 CYP3A4 is the main enzyme involved in the metabolism of macitentan and in the formation of its active metabolite, with minor contribution from CYP2C8, CYP2C9, and CYP2C19 enzymes (see section 5.2). Macitentan and its active metabolite do not have clinically relevant inhibitory or inducing effects on cytochrome P450 enzymes.</p><p>&nbsp;</p><p>Macitentan and its active metabolite are not inhibitors of hepatic or renal uptake transporters at clinically relevant concentrations, including the organic anion transporting polypeptides (OATP1B1 and OATP1B3). Macitentan and its active metabolite are not relevant substrates of OATP1B1 and OATP1B3 but enter the liver by passive diffusion.</p><p>&nbsp;</p><p>Macitentan and its active metabolite are not inhibitors of hepatic or renal efflux pumps at clinically relevant concentrations, including the multi-drug resistance protein (P-gp, MDR-1) and multidrug and toxin extrusion transporters (MATE1 and MATE2-K). Macitentan is not a substrate for P-gp/MDR-1.</p><p>&nbsp;</p><p>At clinically relevant concentrations, macitentan and its active metabolite do not interact with proteins involved in hepatic bile salt transport, i.e., the bile salt export pump (BSEP) and the sodium-dependent taurocholate co-transporting polypeptide (NTCP).</p><p>&nbsp;</p><p><em><u>In vivo </u></em><u>studies</u></p><p>&nbsp;</p><p>&nbsp;</p><p><em>Strong CYP3A4 inducers: </em>Concomitant treatment with rifampicin 600 mg daily, a potent inducer of CYP3A4, reduced the steady-state exposure to macitentan by 79% but did not affect the exposure to the active metabolite. Reduced efficacy of macitentan in the presence of a potent inducer of CYP3A4 such as rifampicin should be considered. The combination of macitentan with strong CYP3A4 inducers should be avoided (see section 4.4).</p><p>&nbsp;</p><p><em>Ketoconazole: </em>In the presence of ketoconazole 400 mg once daily, a strong CYP3A4 inhibitor, exposure to macitentan increased approximately 2-fold. The predicted increase was approximately 3-fold in the presence of ketoconazole 200 mg twice daily using physiologically based pharmacokinetic (PBPK) modelling. The uncertainties of such modelling should be considered. Exposure to the active metabolite of macitentan was reduced by 26%. Caution should be exercised when macitentan is administered concomitantly with strong CYP3A4 inhibitors (see section 4.4).</p><p>&nbsp;</p><p><em>Fluconazole</em>: In the presence of fluconazole 400 mg daily, a moderate dual inhibitor of CYP3A4 and CYP2C9, exposure to macitentan may increase approximately 3.8-fold based on PBPK modelling. However, there was no clinically relevant change in exposure to the active metabolite of macitentan. The uncertainties of such modelling should be considered. Caution should be exercised when macitentan is administered concomitantly with moderate dual inhibitors of CYP3A4 and CYP2C9 (e.g., fluconazole and amiodarone) (see section 4.4).</p><p>&nbsp;</p><p>Caution should also be exercised when macitentan is administered concomitantly with both a moderate CYP3A4 inhibitor (e.g., ciprofloxacin, cyclosporine, diltiazem, erythromycin, verapamil) and moderate CYP2C9 inhibitor (e.g., miconazole, piperine) (see section 4.4).</p><p>&nbsp;</p><p><em>Warfarin: </em>Macitentan given as multiple doses of 10 mg once daily had no effect on exposure to S-warfarin (CYP2C9 substrate) or R-warfarin (CYP3A4 substrate) after a single dose of 25 mg warfarin. The pharmacodynamic effect of warfarin on International Normalised Ratio (INR) was</p><p>&nbsp;</p><p>&nbsp;</p><p>not affected by macitentan. The pharmacokinetics of macitentan and its active metabolite were not affected by warfarin.</p><p>&nbsp;</p><p><em>Sildenafil: </em>At steady-state, the exposure to sildenafil 20 mg three times a day was increased by 15% during concomitant administration of macitentan 10 mg once daily. Sildenafil, a CYP3A4 substrate, did not affect the pharmacokinetics of macitentan, while there was a 15% reduction in the exposure to the active metabolite of macitentan. These changes are not considered clinically relevant. In a placebo-controlled trial in patients with PAH, the efficacy and safety of macitentan in combination with sildenafil were demonstrated.</p><p>&nbsp;</p><p><em>Cyclosporine A: </em>Concomitant treatment with cyclosporine A 100 mg twice daily, a combined CYP3A4 and OATP inhibitor, did not alter the steady-state exposure to macitentan and its active metabolite to a clinically relevant extent.</p><p>&nbsp;</p><p><em>Hormonal contraceptives: </em>Macitentan 10 mg once daily did not affect the pharmacokinetics of an oral contraceptive (norethisterone 1 mg and ethinyl estradiol 35 &mu;g).</p><p>&nbsp;</p><p><em>Breast cancer resistance protein (BCRP) substrate drugs: </em>Macitentan 10 mg once daily did not affect the pharmacokinetics of a BCRP substrate drug (riociguat 1 mg; rosuvastatin 10 mg).</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>Interaction studies have only been performed in adults.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Use in women of childbearing potential/Contraception in males and females</u></p><p>Opsumit treatment should only be initiated in women of childbearing potential when the absence of pregnancy has been verified, appropriate advice on contraception provided, and reliable contraception is practised (see sections 4.3 and 4.4). Women should not become pregnant for 1</p><p>&nbsp;</p><p>&nbsp;</p><p>month after discontinuation of Opsumit. Monthly pregnancy tests during treatment with Opsumit are recommended to allow the early detection of pregnancy.</p><p>&nbsp;</p><p><u>Pregnancy</u></p><p>There are no data from the use of macitentan in pregnant women. Studies in animals have shown reproductive toxicity (see section 5.3). The potential risk for humans is still unknown. Opsumit is contraindicated during pregnancy and in women of childbearing potential who are not using reliable contraception (see section 4.3).</p><p>&nbsp;</p><p><u>Breastfeeding</u></p><p>It is unknown whether macitentan is excreted in human milk. In rats, macitentan and its metabolites are excreted into milk during lactation (see section 5.3). A risk to the breastfeeding child cannot be excluded. Opsumit is contraindicated during breastfeeding (see section 4.3).</p><p>&nbsp;</p><p><u>Male fertility</u></p><p>The development of testicular tubular atrophy in male animals was observed after treatment with macitentan (see section 5.3). The relevance of this finding to humans is unknown, but a deterioration of spermatogenesis cannot be excluded.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Macitentan has minor influence on the ability to drive and use machines. No studies on the effects on the ability to drive and use machines have been performed. However, undesirable effects may occur (e.g., headache, hypotension) that may influence the ability to drive and use machines (see section 4.8).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile.</u></p><p>&nbsp;</p><p>&nbsp;</p><p>The most commonly reported adverse reactions are nasopharyngitis (14%), headache (13.6%) and anaemia (13.2%, see section 4.4). The majority of adverse reactions are mild to moderate in intensity.</p><p><u>Tabulated list of adverse reactions</u></p><p>&nbsp;</p><p>The safety of macitentan has been evaluated in a long-term placebo-controlled trial of 742 patients with symptomatic PAH (SERAPHIN study). The mean treatment duration was 103.9 weeks in the macitentan 10 mg group, and 85.3 weeks in the placebo group. Adverse reactions associated with macitentan obtained from this clinical study are tabulated below.</p><p>Frequencies are defined as: very common (&ge; 1/10); common (&ge; 1/100 to &lt; 1/10); uncommon (&ge; 1/1,000 to &lt; 1/100); rare (&ge; 1/10,000 to &lt; 1/1,000); very rare (&lt; 1/10,000); not known (cannot be estimated from the available data).</p><p><u>Tabulated summary of adverse reactions</u></p><p>&nbsp;</p><p>In the table below all adverse reactions, which occurred at an incidence greater than placebo are listed by system organ class and frequency (very common (&ge; 1/10), common (&ge; 1/100 to &lt; 1/10), uncommon (&ge; 1/1,000 to &lt; 1/100) and rare (&ge; 1/10,000 to &lt; 1/1,000)). Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>System organ class</strong></p></td><td style="vertical-align:top"><p><strong>Frequency</strong></p></td><td style="vertical-align:top"><p><strong>Adverse reaction</strong></p></td></tr><tr><td rowspan="5" style="vertical-align:top"><p>Infections and infestations</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Nasopharyngitis</p></td></tr><tr><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Bronchitis</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Pharyngitis</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Influenza</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Urinary tract infection</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Blood&nbsp; &nbsp;and&nbsp; &nbsp;lymphatic&nbsp;&nbsp;&nbsp; system disorders</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Anaemia,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; haemoglobin decrease<sup>5</sup></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Leukopenia<sup>6</sup></p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Thrombocytopenia<sup>7</sup></p></td></tr><tr><td style="vertical-align:top"><p>Hepatobiliary disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Aminotransferase elevations<sup>4</sup></p></td></tr><tr><td style="vertical-align:top"><p>Immune system disorders</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Hypersensitivity reactions (e.g., angioedema, pruritus, rash)<sup>1</sup></p></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Headache</p></td></tr><tr><td style="vertical-align:top"><p>Vascular disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Hypotension<sup>2</sup></p></td></tr><tr><td style="vertical-align:top"><p>Respiratory,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; thoracic&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and mediastinal disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Nasal congestion<sup>1</sup></p></td></tr><tr><td style="vertical-align:top"><p>General&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; disorders&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and administration site conditions</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Oedema, fluid retention<sup>3</sup></p></td></tr></tbody></table><p>Data derived from pooled placebo-controlled studies. <u>Description of selected adverse reactions</u></p><p>Hypotension has been associated with the use of ERAs including macitentan. In a long-term double-blind study in patients with PAH, hypotension was reported for 7.0% and 4.4% of patients on macitentan 10 mg and placebo, respectively. This corresponded to 3.5 events / 100 patient-years on macitentan 10 mg compared to 2.7 events / 100 patient-years on placebo.</p><p>Oedema/fluid retention has been associated with the use of ERAs including macitentan. In a long-term double-blind study in patients with PAH, the incidence of oedema AEs in the macitentan 10 mg and placebo treatment groups was 21.9% and 20.5%, respectively. In a double-blind study in patients with idiopathic pulmonary fibrosis, the incidence of peripheral oedema AEs in the macitentan and placebo treatment groups was 11.8% and 6.8%, respectively. In two double-blind clinical studies in patients with digital ulcers associated with systemic sclerosis, the incidences of peripheral oedema AEs ranged from 13.4% to 16.1% in the macitentan 10 mg groups and from 6.2% to 4.5% in the placebo groups.</p><p><strong><em>Laboratory abnormalities</em></strong></p><p>&nbsp;</p><p><strong><em>&nbsp;</em></strong></p><p><u>Liver aminotransferases</u></p><p>&nbsp;</p><p>The incidence of aminotransferase elevations (ALT/AST) &gt; 3 &times; ULN was 3.4% on macitentan 10 mg and 4.5% on placebo in a double-blind study in patients with PAH. Elevations &gt; 5 &times; ULN occurred in 2.5% of patients on macitentan 10 mg versus 2% of patients on placebo.</p><p><u>Haemoglobin</u></p><p>&nbsp;</p><p>In a double-blind study in patients with PAH, macitentan 10 mg was associated with a mean decrease in haemoglobin versus placebo of 1 g/dL. A decrease from baseline in haemoglobin concentration to below 10 g/dL was reported in 8.7% of patients treated with macitentan 10 mg and 3.4% of placebo treated patients.</p><p><u>White blood cells</u></p><p>&nbsp;</p><p>In a double-blind study in patients with PAH, macitentan 10 mg was associated with a decrease in mean leucocyte count from baseline of 0.7 &times; 10<sup>9</sup>/L versus no change in placebo-treated patients.</p><p><u>Platelets</u></p><p>&nbsp;</p><p>In a double-blind study in patients with PAH, macitentan 10 mg was associated with a decrease in mean platelet count of 17 &times; 10<sup>9</sup>/L, versus a mean decrease of 11 &times; 10<sup>9</sup>/L in placebo-treated patients.</p><p><u>Long-term safety</u></p><p>&nbsp;</p><p>Of the 742 patients who participated in the pivotal SERAPHIN double-blind study, 550 patients entered a long-term open-label (OL) extension study. (The OL cohort included 182 patients who continued on macitentan 10 mg and 368 patients who received placebo or macitentan 3 mg and crossed over to macitentan 10 mg.)</p><p>Long-term follow-up of these 550 patients for a median exposure of 3.3 years and a maximum exposure of 10.9 years showed a safety profile that was consistent as described above during the SERAPHIN double-blind phase.</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>&nbsp;</p><p>The safety of macitentan in children and adolescents below 18 years has not yet been established. <u>Reporting of suspected adverse reactions</u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions (see details below)</p><p><u>Reporting of suspected adverse reactions</u></p><p>&nbsp;</p><p>&bull;&nbsp; Saudi Arabia<em>:</em></p><p><strong><em>&nbsp;</em></strong></p><p><!--[if gte vml 1]><o:wrapblock><v:shapetype
  id="_x0000_t202" coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
  <v:stroke joinstyle="miter"/>
  <v:path gradientshapeok="t" o:connecttype="rect"/>
 </v:shapetype><v:shape id="_x0000_s1026" type="#_x0000_t202" style='position:absolute;
  margin-left:84.6pt;margin-top:9.55pt;width:402.4pt;height:99.5pt;z-index:-15727104;
  mso-wrap-distance-left:0;mso-wrap-distance-right:0;
  mso-position-horizontal-relative:page' filled="f" strokeweight=".48pt">
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoBodyText style='margin-top:0in;margin-right:81.7pt;margin-bottom:
     0in;margin-left:13.3pt;margin-bottom:.0001pt;text-indent:-3.0pt;
     line-height:192%'>The National Pharmacovigilance and Drug Safety Centre
     (NPC)<span style='letter-spacing:-2.85pt'> </span>o<span style='letter-spacing:
     -.05pt'> </span>SFDA<span style='letter-spacing:-.05pt'> </span>Call
     Center: 19999<o:p></o:p></p>
     <p class=MsoBodyText style='margin-left:19.3pt;text-indent:-9.2pt;
     mso-list:l1 level1 lfo1;tab-stops:19.35pt'><![if !supportLists]><span
     style='mso-list:Ignore'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
     </span></span><![endif]><span dir=LTR></span><a
     href="mailto:npc.drug@sfda.gov.sa"><span style='color:windowtext;
     text-decoration:none;text-underline:none'>E-mail:npc.drug@sfda.gov.sa</span></a><o:p></o:p></p>
     <p class=MsoBodyText style='margin-top:6.8pt;margin-right:0in;margin-bottom:
     0in;margin-left:19.3pt;margin-bottom:.0001pt;text-indent:-9.2pt;
     mso-list:l1 level1 lfo1;tab-stops:19.35pt'><![if !supportLists]><span
     style='mso-list:Ignore'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
     </span></span><![endif]><span dir=LTR></span>Website:https://ade.sfda.gov.sa/<o:p></o:p></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:shape><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><img width="542" height="138" alt="Text Box: The National Pharmacovigilance and Drug Safety Centre (NPC) o SFDA Call Center: 19999
o	E-mail:npc.drug@sfda.gov.sa
o	Website:https://ade.sfda.gov.sa/
" src="file:///C:/Users/Pc/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif" /></td></tr></tbody></table><p><!--[if gte vml 1]></o:wrapblock><![endif]--></p><p>&nbsp;</p><p><strong><em>&nbsp;</em></strong></p><p><strong>o Other GCC States:</strong></p><p>Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Macitentan has been administered as a single dose of up to 600 mg to healthy subjects. Adverse reactions of headache, nausea, and vomiting were observed. In the event of an overdose, standard supportive measures must be taken, as required. Due to the high degree of protein binding of macitentan, dialysis is unlikely to be effective</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: anti-hypertensives, anti-hypertensives for pulmonary arterial hypertension. ATC code: C02KX04.</p><p><u>Mechanism of action</u></p><p>&nbsp;</p><p>&nbsp;</p><p>Endothelin (ET)-1 and its receptors (ETA and ETB) mediate a variety of effects such as vasoconstriction, fibrosis, proliferation, hypertrophy, and inflammation. In disease conditions such as PAH, the local ET system is upregulated and is involved in vascular hypertrophy and in organ damage.</p><p>Macitentan is an orally active potent endothelin receptor antagonist, active on both ETA and ETB receptors and approximately 100-fold more selective for ETA as compared to ETB <em>in vitro</em>. Macitentan displays high affinity and sustained occupancy of the ET receptors in human pulmonary arterial smooth muscle cells. This prevents endothelin-mediated activation of second messenger systems that result in vasoconstriction and smooth muscle cell proliferation.</p><p><u>Clinical efficacy and safety</u></p><p>&nbsp;</p><p><em>Efficacy in patients with pulmonary arterial hypertension</em></p><p><em>&nbsp;</em></p><p>A multicenter, double-blind, placebo-controlled, parallel-group, event-driven, Phase 3 outcome study (AC-055-302/SERAPHIN) was conducted in 742 patients with symptomatic PAH, who were randomised to three treatment groups (placebo [N = 250], 3 mg [N = 250] or 10 mg [N = 242] of macitentan once daily), to assess the long-term effect on morbidity or mortality.</p><p>At baseline, the majority of enrolled patients (64%) were treated with a stable dose of specific therapy for PAH, either oral phosphodiesterase inhibitors (61%) and/or inhaled/oral prostanoids (6%).</p><p>The primary endpoint was the time to first occurrence of a morbidity or mortality event, up to the end of double-blind treatment, defined as death, or atrial septostomy, or lung transplantation, or initiation of intravenous (i.v.) or subcutaneous (s.c.) prostanoids, or other worsening of PAH. Other worsening of PAH was defined as the presence of all of the three following components: a sustained decrease in 6-minute walk distance (6MWD) of at least 15% from baseline; worsening of PAH symptoms (worsening of WHO FC or right heart failure); and need for new treatment for PAH. All events were confirmed by an independent adjudication committee, blinded to treatment allocation.</p><p>&nbsp;</p><p>&nbsp;</p><p>All patients were followed up to end-of-study (EOS) for vital status. EOS was declared when the predefined number of primary endpoint events was reached. In the period between end-of- treatment (EOT) and EOS, patients could receive open-label macitentan 10 mg or alternative PAH therapy. The overall median double-blind treatment duration was 115 weeks (up to a maximum of 188 weeks on macitentan).</p><p>The mean age of all patients was 46 years (range 12&ndash;85 years of age, including 20 patients below 18, 706 patients between 18&ndash;74 years, and 16 patients aged 75 and older) with the majority of subjects being Caucasian (55%) and female (77%). Approximately 52%, 46%, and 2% of patients were in WHO FC II, III, and IV, respectively.</p><p>Idiopathic or heritable PAH was the most common aetiology in the study population (57%), followed by PAH due to connective tissue disorders (31%), PAH associated with corrected simple congenital heart disease (8%), and PAH associated with other aetiologies (medicinal products and toxins [3%] and HIV [1%]).</p><p><u>Outcome endpoints</u></p><p>&nbsp;</p><p>Treatment with macitentan 10 mg resulted in a 45% risk reduction (hazard ratio [HR] 0.55; 97.5% CI: 0.39 to 0.76; logrank p &lt; 0.0001) of the composite morbidity-mortality endpoint up to EOT when compared to placebo [Figure 1 and Table 1]. The treatment effect was established early and was sustained.</p><p>Efficacy of macitentan 10 mg on the primary endpoint was consistent across subgroups of age, sex, ethnic origin, geographical region, aetiology, by monotherapy or in combination with another PAH therapy and by WHO FC (I/II and III/IV).</p><p>Figure 1 Kaplan-Meier estimates of the first morbidity-mortality event in SERAPHIN</p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><!--[if gte vml 1]><v:shapetype
 id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
 path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="image1.jpeg" o:spid="_x0000_i1025" type="#_x0000_t75"
 style='width:335.25pt;height:305.25pt;visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/Pc/AppData/Local/Temp/msohtmlclip1/01/clip_image001.jpg"
  o:title=""/>
</v:shape><![endif]--><img width="447" height="407" alt="" src="file:///C:/Users/Pc/AppData/Local/Temp/msohtmlclip1/01/clip_image001.jpg" /></p><p><strong>&nbsp;</strong></p><p><strong>Table 1 Summary of outcome events</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2" style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>Endpoints &amp; statistics</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Patients with events</strong></p></td><td colspan="4" style="vertical-align:top"><p><strong>Treatment comparison: macitentan 10 mg vs placebo</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>Placebo (N = 250)</strong></p></td><td style="vertical-align:top"><p><strong>Macitentan 10 mg</strong></p><p><strong>(N = 242)</strong></p></td><td style="vertical-align:top"><p><strong>Absolute risk reduction</strong></p></td><td style="vertical-align:top"><p><strong>Relative&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; risk reduction</strong></p><p><strong>(97.5% CI)</strong></p></td><td style="vertical-align:top"><p><strong>HR </strong><strong>a</strong></p><p><strong>(97.5% CI)</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>Logrank p-value</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Morbidity- mortality event </strong><strong>b</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>53%</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>37%</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>16%</p></td><td style="vertical-align:top"><p>45%</p><p>(24%; 61%)</p></td><td style="vertical-align:top"><p>0.55</p><p>(0.39; 0.76)</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>&lt; 0.0001</p></td></tr><tr><td style="vertical-align:top"><p><strong>Death </strong><strong>c</strong></p><p><strong>n (%)</strong></p></td><td style="vertical-align:top"><p>19 (7.6%)</p></td><td style="vertical-align:top"><p>14 (5.8%)</p></td><td style="vertical-align:top"><p>2%</p></td><td style="vertical-align:top"><p>36%</p><p>(&minus;42%; 71%)</p></td><td style="vertical-align:top"><p>0.64</p><p>(0.29; 1.42)</p></td><td style="vertical-align:top"><p>0.20</p></td></tr><tr><td style="vertical-align:top"><p><strong>Worsening of</strong></p></td><td style="vertical-align:top"><p>93 (37.2%)</p></td><td style="vertical-align:top"><p>59 (24.4%)</p></td><td style="vertical-align:top"><p>13%</p></td><td style="vertical-align:top"><p>49%</p></td><td style="vertical-align:top"><p>0.51</p></td><td style="vertical-align:top"><p>&lt; 0.0001</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>PAH n (%)</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td rowspan="2" style="vertical-align:top"><p>(27%; 65%)</p></td><td rowspan="2" style="vertical-align:top"><p>(0.35; 0.73)</p></td><td rowspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>i.v./s.c. prostanoid initiation n (%)</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>6 (2.4%)</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>1 (0.4%)</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>2%</p></td></tr><tr><td colspan="7" style="vertical-align:top"><p><sup>a</sup> = based on Cox&#39;s Proportional Hazards Model</p><p><sup>b</sup> = % of patients with an event at 36 months = 100 &times; (1 - KM estimate)</p><p><sup>c</sup>= all cause death up to EOT regardless of prior worsening</p></td></tr></tbody></table><p>The number of deaths of all causes up to EOS on macitentan 10 mg was 35 versus 44 on placebo (HR 0.77; 97.5% CI: 0.46 to 1.28).</p><p>The risk of PAH-related death or hospitalisation for PAH up to EOT was reduced by 50% (HR 0.50; 97.5% CI: 0.34 to 0.75; logrank p &lt; 0.0001) in patients receiving macitentan 10 mg (50 events) compared to placebo (84 events). At 36 months, 44.6% of patients on placebo and 29.4% of patients on macitentan 10 mg (Absolute Risk Reduction = 15.2%) had been hospitalised for PAH or died from a PAH-related cause.</p><p><u>Symptomatic endpoints</u></p><p>&nbsp;</p><p>Exercise capacity was evaluated as a secondary endpoint. Treatment with macitentan 10 mg at Month 6 resulted in a placebo-corrected mean increase in 6MWD of 22 meters (97.5% CI: 3 to 41; p = 0.0078). Evaluation of 6MWD by functional class resulted in a placebo-corrected mean increase from baseline to Month 6 in FC III/IV patients of 37 meters (97.5% CI: 5 to 69) and in FC I/II of 12 meters (97.5% CI: -8 to 33). The increase in 6MWD achieved with macitentan was maintained for the duration of the study.</p><p>Treatment with macitentan 10 mg at Month 6 led to a 74% higher chance of WHO FC improvement relative to placebo (risk ratio 1.74; 97.5% CI: 1.10 to 2.74; p = 0.0063).</p><p>Macitentan 10 mg improved quality of life assessed by the SF-36 questionnaire.</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Haemodynamic endpoints</u></p><p>&nbsp;</p><p>Haemodynamic parameters were assessed in a subset of patients (placebo [N = 67], macitentan 10 mg [N = 57]) after 6 months of treatment. Patients treated with macitentan 10 mg achieved a median reduction of 36.5% (97.5% CI: 21.7 to 49.2%) in pulmonary vascular resistance and an increase of 0.58 L/min/m2 (97.5% CI: 0.28 to 0.93 L/min/m<sup>2</sup>) in cardiac index compared to placebo.</p><p><em>Long-term data in PAH</em></p><p><em>&nbsp;</em></p><p>In long-term follow-up of 242 patients who were treated with macitentan 10 mg in the double- blind (DB) phase of the SERAPHIN study, 182 of which continued with macitentan in the open- label (OL) extension study (SERAPHIN OL) (DB/OL cohort), Kaplan-Meier estimates of survival at 1, 2, 5, 7 and 9 years were 95%, 89%, 73%, 63% and 53%, respectively. The median follow-up time was 5.9 years.</p><p><u>Paediatric population</u></p><p>&nbsp;</p><p>The European Medicines Agency has deferred the obligation to submit the results of studies with macitentan in all subsets of the paediatric population for PAH (see section 4.2 for information on paediatric use).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The pharmacokinetics of macitentan and its active metabolite have mainly been documented in healthy subjects. Exposure to macitentan in patients with PAH was approximately 1.2-fold greater than in healthy subjects. The exposure to the active metabolite in patients, which is approximately 5-fold less potent than macitentan, was approximately 1.3-fold higher than in healthy subjects. The pharmacokinetics of macitentan in PAH patients were not influenced by the severity of the disease.</p><p>After repeated administration, the pharmacokinetics of macitentan are dose-proportional up to and including 30 mg.</p><p><u>Absorption</u></p><p>&nbsp;</p><p>&nbsp;</p><p>Maximum plasma concentrations of macitentan are achieved about 8 hours after administration. Thereafter, plasma concentrations of macitentan and its active metabolite decrease slowly, with an apparent elimination half-life of approximately 16 hours and 48 hours, respectively.</p><p>In healthy subjects, the exposure to macitentan and its active metabolite is unchanged in the presence of food and, therefore, macitentan may be taken with or without food.</p><p><u>Distribution</u></p><p>&nbsp;</p><p>Macitentan and its active metabolite are highly bound to plasma proteins (&gt; 99%), primarily to albumin and to a lesser extent to alpha1-acid glycoprotein. Macitentan and its active metabolite ACT-132577 are well distributed into tissues as indicated by an apparent volume of distribution (Vss/F) of approximately 50 L and 40 L for macitentan and ACT-132577, respectively.</p><p><u>Biotransformation</u></p><p>&nbsp;</p><p>Macitentan has four primary metabolic pathways. Oxidative depropylation of the sulfamide yields a pharmacologically active metabolite. This reaction is dependent on the cytochrome P450 system, mainly CYP3A4 (approximately 99%) with minor contributions of CYP2C8, CYP2C9 and CYP2C19. The active metabolite circulates in human plasma and may contribute to the pharmacological effect. Other metabolic pathways yield products without pharmacological activity. For these pathways, CYP2C9 plays a predominant role with minor contributions from CYP2C8, CYP2C19 and CYP3A4.</p><p><u>Elimination</u></p><p>&nbsp;</p><p>Macitentan is only excreted after extensive metabolism. The major excretion route is via urine, accounting for about 50% of the dose.</p><p><u>Special populations</u></p><p>&nbsp;</p><p>There is no clinically relevant effect of age, sex or ethnic origin on the pharmacokinetics of macitentan and its active metabolite.</p><p><u>Renal impairment</u></p><p>&nbsp;</p><p>&nbsp;</p><p>Exposure to macitentan and its active metabolite was increased by 1.3- and 1.6-fold, respectively, in patients with severe renal impairment. This increase is not considered clinically relevant (see sections 4.2 and 4.4).</p><p><u>Hepatic impairment</u></p><p>&nbsp;</p><p>Exposure to macitentan was decreased by 21%, 34%, and 6% and, for the active metabolite by 20%, 25%, and 25% in subjects with mild, moderate or severe hepatic impairment, respectively. This decrease is not considered clinically relevant (see sections 4.2 and 4.4).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In dogs, macitentan decreased blood pressure at exposures similar to the therapeutic human exposure. Intimal thickening of coronary arteries was observed at 17-fold the human exposure after 4 to 39 weeks of treatment. Due to the species-specific sensitivity and the safety margin, this finding is considered not relevant for humans.</p><p>Increased liver weight and hepatocellular hypertrophy were observed in mice, rats and dogs after treatment with macitentan. These changes were largely reversible and considered non-adverse adaptations of the liver to increased metabolic demand.</p><p>Macitentan induced minimal to slight mucosal hyperplasia and inflammatory infiltration in the submucosa of the nasal cavity in the mouse carcinogenicity study at all doses. No nasal cavity findings were noted in the 3-month mouse toxicity study or in rat and dog studies.</p><p>Macitentan was not genotoxic in a standard battery of <em>in vitro </em>and <em>in vivo </em>assays. Macitentan was not phototoxic <em>in vivo </em>after single dose at exposures of up to 24-fold the human exposure. Carcinogenicity studies of 2 years&#39; duration did not reveal a carcinogenic potential at exposures 18-fold and 116-fold the human exposure in rats and mice, respectively.</p><p>Testicular tubular dilatation was observed in chronic toxicity studies with male rats and dogs with safety margins of 11.6 and 5.8, respectively. Tubular dilatation was fully reversible. After 2 years of treatment, testicular tubular atrophy was seen in rats at 4-fold the human exposure. Hypospermatogenesis was observed in the life-long carcinogenicity study in rats and in the</p><p>&nbsp;</p><p>&nbsp;</p><p>repeat-dose toxicity studies in dogs at exposures that provide safety margins of 9.7 in rats and 23 in dogs. The safety margins for fertility were 18 for male and 44 for female rats. No testicular findings were noted in mice after treatment up to 2 years.</p><p>Macitentan was teratogenic in rabbits and rats at all doses tested. In both species there were cardiovascular and mandibular arch fusion abnormalities.</p><p>Administration of macitentan to female rats from late pregnancy through lactation at maternal exposures 5-fold the human exposure, caused reduced pup survival and impairment of the reproductive capability of the offspring, which was exposed to macitentan during late intrauterine life and via the milk during the suckling period.</p><p>Treatment of juvenile rats from postnatal Day 4 to Day 114 caused reduced body weight gain leading to secondary effects on development (slight delay of descensus testis, reversible reduction of long-bone length, prolonged estrous cycle). Slightly increased pre- and post- implantation loss, decreased mean number of pups, and decreased testis and epididymis weights, were observed at exposures 7-fold the human exposure. Testicular tubular atrophy, and minimal effects on reproductive variables and sperm morphology were recorded at exposures 3.8-fold the human exposure.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Opsutin tablets 10 mg:</u></p><p>Lactose Monohydrate, Sodium Starch Glycolate (Type-A), Povidone (K 30), Polysorbate 80, Sodium Stearyl Fumarate, Purified Water.</p><p><strong>Film-coating composition &ndash; </strong>Polyvinyl alcohol (E1203), Titanium Dioxide (E171), Talc (E553b), Lecithin (E322), Xanthan Gum (E415).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>NA</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 months
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>NA</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Opsutin is Supplied in 10&rsquo;s Blister pack</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>NA</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Saudi Amarox Industrial Company, Aljameah Street, Malaz quarter, Riyadh 11441, Saudi Arabia
Tel: +966 11 477 2215

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                December-2022
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>